去纤维钠药物说明书

Medication instructions

Common name: defibrinoside

Product name: Defitelio

All names: Defibrotide, Defitelio, defiteli, defibrotide, defibrotide sodium

Indications:

It is suitable for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Usage and dosage:

The recommended dose for adult and pediatric patients is 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT (hematopoietic stem cell transplant) preparation protocol.

Give Defibrotide for a minimum of 21 days. If signs and symptoms of hepatic veno-occlusive disease have not resolved after 21 days, continue defibrination until resolution of hepatic veno-occlusive disease or for a maximum of 60 days.

Defibrinated sodium must be diluted before infusion. Do not coadminister defibrotide sodium with other intravenous drugs at the same time and in the same intravenous line.

Adverse reactions:

Hypotension, diarrhea, vomiting, nausea, nosebleeds, allergic reactions.

Taboo:

Hypersensitivity to any ingredient in sodium defibrination.

Use in combination with systemic anticoagulation or fibrinolytic therapy.

Things to note:

Bleeding: Defibrotide increases plasmin activity in vitro and may increase the risk of bleeding in VOD patients after hematopoietic stem cell transplantation (HSCT). Do not initiate Defitelio treatment in patients with active bleeding.

Hypersensitivity reactions: Less than 2% of patients treated with defibrotide have experienced allergic reactions. These reactions include rash, urticaria, and angioedema.

Storage:

Store at 20°C-25°C (68°F-77°F); excursions allowed between 15°C and 30°C (59°F and 86°F).

The above is the drug instructions, I hope it will be helpful to you.